Senseonics Partners with Beta Bionics to Integrate Eversense 365 with iLet Bionic Pancreas
SENS sits 83% above its 52-week low of $4.79.
Summary
Senseonics announced a strategic partnership with Beta Bionics to integrate its Eversense 365 continuous glucose monitor with the iLet Bionic Pancreas automated insulin delivery system. The integration is expected to be completed in Q4 2026, with commercial launch planned for the same quarter, subject to testing and regulatory requirements. This expands Senseonics' reach into the automated insulin delivery market, building on its first pump integration. The partnership could accelerate adoption of Eversense 365 among iLet users, a growing community. Watch for completion of integration activities and any regulatory milestones in Q4 2026.
At the time of this announcement, SENS was trading at $8.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460.5M. The 52-week trading range was $4.79 to $11.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.